Abstract
These retrospective observational data were collected to understand the role of vasopressin in the hemodynamic management of neonates with shock in a tertiary-level NICU over a period of 2 years. This included 28 neonate who received vasopressin for different clinical states with hypotension like septic shock, MAS with PPHN, Sepsis with PPHN, PPHN with CDH, HOCM, and even in end-organ injury (AKI) with sepsis. The response to vasopressin was 78.5% with improved signs of shock. The overall mortality rate was 15%. This is an attempt to understand vasopressin use in very sick neonates. Randomized controlled trials are required for its use as a treatment protocol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
